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Abstract
Background: Previous studies have provided the initial evidence for construct validity and test-retest reliability of
the Mayo Hip Score. Instruments used for Total Hip Arthroplasty (THA) outcomes assessment should be valid,
reliable and responsive to change. Our main objective was to examine the responsiveness to change, association
with subsequent revision and the construct validity of the Mayo hip score.
Methods: Discriminant ability was assessed by calculating effect size (ES), standardized response mean (SRM) and
Guyatt’s responsiveness index (GRI). Minimal clinically important difference (MCII) and moderate improvement
thresholds were calculated. We assessed construct validity by examining association of scores with preoperative
patient characteristics and correlation with Harris hip score, and assessed association of scores with the risk of
subsequent revision.
Results: Five thousand three hundred seven provided baseline data; of those with baseline data, 2,278 and 2,089
(39 %) provided 2- and 5-year data, respectively. Large ES, SRM and GRI ranging 2.66–2.78, 2.42–2.61 and 1.67–1.88
were noted for Mayo hip scores with THA, respectively. The MCII and moderate improvement thresholds were
22.4–22.7 and 39.4–40.5 respectively. Hazard ratios of revision surgery were higher with lower final score or less
improvement in Mayo hip score at 2-years and borderline significant/non-significant at 5-years, respectively: (1)
score ≤55 with hazard ratios of 2.24 (95 % CI, 1.45, 3.46; p = 0.0003) and 1.70 (95 % CI, 1.00, 2.92; p = 0.05) of implant
revision subsequently, compared to 72-80 points; (2) no improvement or worsening score with hazard ratios 3.94
(95 % CI, 1.50, 10.30; p = 0.005) and 2.72 (95 % CI, 0.85,8.70; p = 0.09), compared to improvement >50-points. Mayo
hip score had significant positive correlation with younger age, male gender, lower BMI, lower ASA class and lower
Deyo-Charlson index (p ≤ 0.003 for each) and with Harris hip scores (p < 0.001).
Conclusions: Mayo Hip Score is valid, sensitive to change and associated with future risk of revision surgery in
patients with primary THA.
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Background
Hip replacement has been termed the operation of the
century [1]. Improvements after total hip arthroplasty
(THA) are often measured using instruments that meas-
ure pain, function and/or quality of life (QOL). Patient-
reported outcomes (PROs) of pain and QOL show
improvement after THA, usually an elective procedure
for the treatment of end-stage hip arthritis. A recent re-
view of key challenges to the assessment of QOL out-
comes in arthroplasty noted that it is critical to assess
psychometric properties of commonly used instruments
[2]. Most studies use composite instruments (pain, func-
tion and QOL) to assess arthroplasty outcomes, the
most common being the Harris Hip Score (HHS) [3, 4].
The Mayo Hip Score, a composite instrument that as-
sesses pain, function and hip mobility, has been used for
THA outcome assessment at our institution (i.e., Mayo
Clinic) for >3 decades. A key difference between the
Mayo Hip Score and the HHS is that Mayo Hip Score is
shorter and does not include range of motion and limb
deformity assessments [5, 6]. Thus, it does not require a
physician’s examination or a goniometer for completion
and can be easily completed by a patient (or a provider).
Previous studies have provided initial evidence for
construct validity and test-retest reliability of the Mayo
Hip Score [5, 6], but other aspects of validity and dis-
criminant ability have not been tested. It is important
that the instruments used for THA outcomes assess-
ment are valid, reliable and responsive to change. Re-
sponsiveness to change is an important attribute of a
PRO instrument, since they are often used to compare
outcomes of technological and surgical innovations in
THA [7, 8]. The objective of this study was to examine
discriminant ability, association with subsequent revision
and examine further construct validity and reliability of
the Mayo Hip Score.
Methods
Study participants and the instrument
The study included patients who had undergone primary
THA at the Mayo Clinic and had completed a Mayo Hip
Score at preoperative and/or one of the two follow-up
periods, i.e. 2- or 5-years post-THA. The institutional re-
view board at the Mayo Clinic approved the study and
waived the requirement for patient consent. The Mayo
Hip Score is a composite scale that consists of pain and
function questions (Additional file 1: Appendix 1). The
total score ranges 0–80; higher score is better. A single
pain question is scored 0–40 points based on pain sever-
ity: no pain, slight, moderate and severe pain scored at
40, 35, 20 and 0 points. Hip function is based on dis-
tance walked (15 points) and the use of support aids
(canes, crutches, walker; 5 points for no aids) for ambu-
lation. Hip mobility is assessed with 4 questions, each
for 5 points: ability to enter and leave a car, ability to
perform foot care, presence of a limp and the ability to
climb stairs. The Mayo Hip Score has been shown to
have test-retest reliability and limited construct validity
[5, 6]. The study period was 1993–2005.
Responsiveness/discriminant validity, construct validity
and association with revision
Responsiveness was assessed by three statistics. We calcu-
lated the effect size (ES) by dividing the change in hip
score from baseline to 2-years by the standard deviation at
baseline (preoperative). An ES of 0.20–0.49 represents a
small change, 0.50–0.79 a medium change, and ≥ 0.80 a
large change, according to Cohen’s rule. The standardized
response mean (SRM) is defined as the mean change in
the patient Mayo hip score divided by the SD of the chan-
ged scores. The Guyatt Responsiveness Index (GRI) is the
ratio of average change in patients identified as improved
(much better and somewhat better combined as one
group) divided by the standard deviation of the change in
patients identified as remaining stable (“no change”) based
on the global rating of hip function change.
We calculated the minimal clinically important im-
provement (MCII) and moderate improvement as im-
provements corresponding to categories “somewhat
better now” and “much better now”, on the following
global question as the anchor: Compared to before sur-
gery, how is your hip? Much better now, somewhat bet-
ter now, the same and worse.
Construct validity was assessed with convergent and
divergent validity. Convergent validity was assessed by
Spearman’s correlation coefficients between Mayo hip
scores and HHS at baseline, 2- and 5-years. We also
assessed convergent validity by assessing Mayo hip
scores for different activity levels (unlimited, some limi-
tation and severe limitation). Divergent validity was
assessed with examining mean Mayo hip scores at 2-
and 5-years post-THA for the different levels of variables
previously shown to be associated with pain/function
outcomes after THA and examining association of these
variables in univariate linear regression with Mayo hip
scores [9–16]: age, gender, American Society of
Anesthesiology (ASA) class and the Deyo-Charlson
index [17], a validated measure of medical comorbidity.
We also assessed association of Mayo hip scores with
the number of joints involved (index hip or up to four
joints including both knees and hips). These models
examining were also subsequently adjusted for baseline
Mayo Hip Scores. Test-retest reliability was assessed
using intra-class coefficient (ICC) [18], by comparing
two ratings on the same individual by patient vs. phys-
ician within 2-weeks of each other.
We examined the associations of the Mayo hip scores
at 2- or 5-years or the change in Mayo hip scores from
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baseline to 2- and 5-years with the risk of subsequent re-
vision THA. Final Mayo hip scores were categorized as
≤55, 56–63, 64–71 and 72–80, based on previously de-
fined categories of excellent, good, fair and poor results
[6]. Change in Mayo hip scores was categorized as ≤0,
1–25, 26–50 vs. >50. We used Cox regression model
and calculated hazard ratios of revision, along with 95 %
confidence intervals. We constructed Kaplan-Meier sur-
vival plots for absolute and change Mayo hip scores.
A p-value of 0.05 or lower was considered significant.
Results
Clinical and demographic features of study cohort are
shown in Additional file 1: Appendix 2. Mean age was
64 years, 51 % were female. 24 % had body mass index
(BMI) of <25 kg/m2 and mean Deyo-Charlson index was
1.0. Mean Mayo hip scores (standard deviation) at base-
line pre-operative and 2- and 5-years post-THA were 33
(14), 72 (12) and 70 (13), respectively. Of all surveys
available, 23–25 % each were for patients with pre-
operative and 2-year and preoperative and 5-year assess-
ment. Non-response rates at 2- and 5-years in those with
preoperative surveys were 36 % and 45 %.
Discriminant validity/Responsiveness to Change: Large
ES, SRM and GRI were noted for Mayo hip scores at
both 2-years and 5-years post-THA (Table 1). MCII esti-
mates were 22.4 at 2-years and 22.7 at 5-years; moderate
improvement thresholds were 40.5 and 39.4, respectively
(Table 1).
Convergent and divergent validity: Younger age, male
gender, lower BMI, lower ASA class and lower Deyo-
Charlson index were each significantly associated with
higher Mayo hip scores at 2- and 5-years post-THA
(p ≤ 0.003 for each; Additional file 1: Appendix 3), while
the total number of joints involved was not significantly
associated. This finding was confirmed in models that
additionally adjusted for baseline preoperative Mayo hip
scores (Additional file 1: Appendix 3). Similar strong asso-
ciations of Mayo hip scores were seen with lower levels of
overall activity limitation and with patient response of
more improvement in their hip (much better, better) on
the global question (Additional file 1: Appendix 3).
Spearman correlation coefficients of Mayo Hip Score
with Harris Hip Score at baseline were 0.91 and 0.93, at
2-years and 5-years respectively (p < 0.001 for all).
Association with Subsequent Implant Revision: Mayo
hip scores of 55 or lower at 2-years were significantly
associated with higher risk of THA revision at 2-years
(p = 0.0003) and with borderline significance at 5-years
(p = 0.05), the risk being 2-times compared to those with
score 72–80 points (Table 2). Compared to improvement
of >50-points in Mayo hip score, patients with no im-
provement or worsening of Mayo hip score at 2-years
after THA had a 3.9 times higher risk of THA revision
subsequently (p = 0.005) and a statistically non-significant
trend at 5-years with 2.7-times odds (p = 0.09; Table 2).
The association of 2- and 5-year final and change scores
on Mayo hip scores with implant survival is shown in
Fig. 1. Absolute Mayo hip scores at 2-years and change in
Mayo hip scores at 2- and 5-years were each significantly
associated with the risk of revision (p < 0.05 each); abso-
lute Mayo hip scores at 5-years showed a non-significant
trend (p = 0.14).
Test-retest reliability: The Mayo hip scores from phys-
ician and patient-administered surveys were numerically
similar, 73 +/- 10 vs. 68 +/- 12, being 5-point (SD, 10)
higher in physician- than patient-assessed surveys. In
contrast, for HHS, respective scores were 91 +/- 12 vs.
81 +/- 14 with a difference of 10 +/- 11 between the
scores. The ICC for Mayo hip score, using the data from
the physician vs. patient-administered, was high at 0.55
(95 % CI: 0.47, 0.63), numerically higher than the ICC
for Harris Hip Score at 0.48 (95 % CI: 0.40, 0.57).
Discussion
In this study, we found that Mayo hip score is a valid
and reliable measure of hip outcomes in patients who
had undergone primary THA. Mayo hip score was also
associated with the risk of revision surgery at 2-years,
both when examined as the final score and as a change
score. These psychometric properties compared well to
the HHS [5, 19–21], which at present is the most com-
monly used outcome instrument for THA outcome as-
sessment [3, 4]. An advantage of the Mayo hip score is
Table 1 Discriminant ability of Mayo hip score and thresholds for clinically meaningful improvements
Discriminant ability statistics
2-year - Baseline value 5-year - Baseline value
Effect Size (ES) 2.78 [n = 2,278] 2.66 [n = 2,089]
Standardized Response Mean (SRM) 2.61 [n = 2,050] 2.42 [n = 1,919]
Guyatt’s Responsiveness Index (GRI) 1.67 [n = 27] 1.88 [n = 37]
Clinically Important Improvement Thresholds, Mean (standard deviation)
Minimally clinically important improvement (MCII) 22.4 (19.5) [n = 122] 22.7 (19.4) [n = 131]
Moderate improvement 40.5 (14.1) [n = 1,928] 39.4 (14.9) [n = 1,788]
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Table 2 The association of Mayo Hip Scores with the risk of THA revision using Cox regression analyses
Hazards of THA Revision (95 % CI) p-value Hazards of THA Revision (95 % CI) p-value
2-year data 5-year data
n = 3,307 with 178 events n = 1,717 with 97 events
Total Mayo Hip Scorea
≤55 vs. 72–80 2.24 (1.45, 3.46) 0.0003 1.70 (1.00, 2.92) 0.05
56–63 vs. 72–80 0.60 (0.24, 1.48) 0.26 1.00 (0.40, 2.52) 0.99
64–71 vs. 72–80 0.80 (0.48, 1.36) 0.42 0.70 (0.35, 1.42) 0.32
2-year data 5-year data
n = 1,904 with 106 events n = 1,080 with 61 events
Mayo Hip Score improvement
≤0 vs. >50 3.94 (1.50, 10.30) 0.005 2.72 (0.85, 8.70) 0.09
1–25 vs. >50 0.88 (0.44, 1.76) 0.71 1.45 (0.70, 3.01) 0.32
26–50 vs. >50 0.87 (0.56, 1.34) 0.52 0.73 (0.40, 1.35) 0.32
aCategorization of Mayo hip score is based on the previously described categories: Excellent result is 72-80 points, good is 64–71 points, fair is 56–63 points, and
poor is ≤55 points by McGrory et al. 1996 [6]










































































Fig. 1 Implant failure (revision) graphs based on the absolute Mayo hip scores at 2-years and 5-years (panels a and b) and change in scores compared
to preoperative (panels c and d) in the subsequent follow-up period. a Absolute Mayo hip scores at 2-years and subsequent revision risk. b Absolute
Mayo hip scores at 5-years and subsequent revision risk. c Improvement in Mayo hip scores at 2-years and subsequent revision risk. d. Improvement in
Mayo hip scores at 5-years and subsequent revision risk. X-axis represents the number of years after the survey completion (survey completion was
2-years post-THA for panels a and c; 5-years post-THA for panels b and d), and y-axis the proportion of patients who underwent revision surgery for
the hip implant
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that either physicians or patients can complete it, as
compared to the HHS that has physician and patient
portions. An excellent agreement between these assess-
ments also indicates that in an appropriate setting, Mayo
hip score may be an alternative to HHS. Several findings
from this validation study deserve further discussion.
First, our study established that Mayo hip score was re-
sponsive to change with large effect sizes and was associ-
ated with risk of subsequent revision at 2-years. This is a
very important finding, considering that one of the main
applications of arthroplasty outcomes instruments is to
compare various surgical or implant types and therefore a
responsive instrument is highly desirable [2]. HHS has
been shown to be responsive with large ES and SRM of
2.5 and 1.8 [21]; respective ES and SRM for Mayo hip
score of 2.8 and 2.6 from our study are comparable. We
also determined the MCII and moderate improvement
thresholds for Mayo hip score, at 2- and 5-years.
The association of Mayo hip score with the risk of fu-
ture revision surgery is particularly impressive, since the
attainment of Mayo Hip Scores at or below 55 points at
2- or 5-years increased the risk of early revision surgery
after each time-point by 2-times, compared to scores
72–80 points (maximum score is 80). This was statisti-
cally significant at 2-years (p = 0.0003) and borderline sta-
tistically significant at 5-years (p = 0.05). A lack of
improvement (or worsening) of Mayo hip score from pre-
operative to 2-years was associated with a 3-4 times higher
revision risk compared to improvement by >50-points.
K-M survival curves describe these findings that both
absolute and change in Mayo hip scores were signifi-
cantly associated with the risk of revision, the only
exception being the association of absolute scores at
5-years that was not statistically significantly associated
with future revision risk (p = 0.14). These findings indicate
that Mayo hip scores might allow screening of early THA
implant failures. This has practical implications, beyond
instrument validation. It may be possible to develop an
early implant risk score for clinical use that incorporates
Mayo hip score (or similar scales) and other risk factors, a
project currently underway.
Second, this study adds significant validation data re-
lated to the construct validity of the Mayo hip score.
Our finding of significant association of Mayo hip scores
at 2- and 5-years with important baseline characteristics
previously shown to impact pain and function outcomes,
i.e. age, gender, BMI, ASA class and Deyo-Charlson
index [9–16], provides critical evidence for its conver-
gent and divergent validity. The high correlation of
Mayo hip score with HHS, a validated outcome instru-
ment [19, 20, 22] and overall activity level, establishes
the construct validity of Mayo hip score for assessment
of outcomes after THA. More validation studies in other
populations such as revision THA, hip arthroscopy,
partial hip replacement may be needed before Mayo hip
score can be used for the assessment of outcomes in
these populations.
We found the Mayo hip score has fair test-retest inter-
rater reliability, which extends the findings from an inde-
pendent sample from our institution (i.e., Mayo Clinic) in
97 THA patients [6]. We found a slightly higher (better)
score in physician- than patient-administered Mayo hip
score, and the difference of 5-points in our study was
slightly higher than the 1.8-point difference in the previ-
ous study. As expected, this difference was slightly smaller
than that for HHS, given its complexity and inclusion of
range of motion and deformity. This indicates the reliabil-
ity of Mayo Hip score is as much as HHS or higher. Inter-
rater ICCs in the range of 0.39 to 0.86 have been reported
for outcome measures in pemphigus [23] with patient vs.
physician scoring, similar to our ICC of 0.55 for Mayo hip
score. A higher ICC would imply that patient and phys-
ician assessments agree closely; however, the ICC seems
numerically better than the most commonly used in-
strument, the HHS, in our study. For a patient-reported
measure such as Mayo hip score, it is not surprising to
see differences in physician completed assessment vs. pa-
tient completed assessment. We recommend that this
PRO be completed by patients, not physicians, and in
studies where both physicians and patients have
completed the survey, MHS scores may not be
interchangeable.
Key advantages of Mayo hip score are that it has fewer
questions than HHS and does not require physician as-
sessment in the clinic. Therefore, it can be sent as a
mailed survey and completed by patients. This can allow
for a rapid and efficient assessment of not only the pa-
tients’ current pain/function status that allows screening
for THA failures during the short and long-term arthro-
plasty follow-up. As suggested in earlier studies, the
Mayo hip score can be coupled with radiographic score
[5] for a more comprehensive assessment. The advent of
telemedicine may allow for a virtual patient visit and
follow-up (mailed survey and remote review of radio-
graphs) that can replace the annual in-person clinician
visit. In an era of health care cost reduction and a de-
clining supply of arthroplasty surgeons [24], this ap-
proach might allow more cost-efficient arthroplasty
follow-up and monitoring.
One must consider the study limitations while inter-
preting study findings. Non-response rates were 36 %
and 45 % at 2- and 5-years, respectively, which could
have potentially affected the study findings. We decided
a priori not to impute values for missing data, since this
was a validation study, and we wanted to only use real
data. It is unclear to us, whether it strengthened or
weakened study findings, since we are unaware of the
impact of non-response on validation statistics. These
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findings may therefore be generalizable only to patients
who regularly respond to post-arthroplasty surveys. The
overall revision rate in the cohort is low, and we may
have missed significant findings due to the rarity of this
outcome.
So, what does this study add? There is already a large
diversity of instruments being used in THA assessments
[25], so why have another instrument? Several instru-
ment in current use in arthroplasty have limited data on
validity and reliability, and we provide assessment of
validity and responsiveness of an instrument that has
been in use in our Total Joint Registry for >3 decades
and is patient self-administered. One challenge in post-
arthroplasty outcome assessment is the use of several
different outcome measures [25]. Harmonization of the
THA outcome instrument use across arthroplasty stud-
ies would be a step forward and will allow comparison
across studies. This effort is currently underway [26].
Conclusions
In summary, this study provides validation data for the
Mayo hip score. Mayo hip score is valid, reliable and
sensitive to change. Mayo hip score is associated with
the risk of subsequent revision surgery. It correlates well
with HHS, the most popular instrument for THA out-
comes assessment and has the advantage that it can be
completed either by the patient or the surgeon. We sug-
gest that this instrument be completed by the patient,
based on the fact that pain and daily function abilities
are best assessed and reported by a patient and that it is
more practical for the patient to complete this instru-
ment than the physician. Clinically meaningful thresh-
olds for Mayo Hip score have been established. In the
era of where PROs are a critical part of patient assess-
ment and follow-up after arthroplasty, the Mayo hip
score may offer an alternative to longer instruments.
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